Prostate Cancer, Version 1.2016.
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
Mohler, JL; Armstrong, AJ; Bahnson, RR; D'Amico, AV; Davis, BJ; Eastham, JA; Enke, CA; Farrington, TA; Higano, CS; Horwitz, EM; Hurwitz, M; Kane, CJ; Kawachi, MH; Kuettel, M; Lee, RJ; Meeks, JJ; Penson, DF; Plimack, ER; Pow-Sang, JM; Raben, D; Richey, S; Roach, M; Rosenfeld, S; Schaeffer, E; Skolarus, TA; Small, EJ; Sonpavde, G; Srinivas, S; Strope, SA; Tward, J; Shead, DA; Freedman-Cass, DA
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)